99 results on '"T, Lavabre-Bertrand"'
Search Results
2. Multiplex Fluorescent RT-PCR to Quantify Leukemic Fusion Transcripts
- Author
-
M. Dupont, A. Goldsborough, T. Levayer, J. Savare, J.M. Rey, J.F. Rossi, J. Demaille, and T. Lavabre-Bertrand
- Subjects
Biology (General) ,QH301-705.5 - Abstract
The detection of chimeric transcripts derived from aberrant chromosomal fusion events provides an exceptionally valuable tool for the diagnosis of leukemia. We have developed a simple, inexpensive, reproducible, and automated method to quantify RT-PCR products. Our approach utilizes fluorescent PCR for the co-amplification of the specific fusion transcript with an internal control (HPRT). We have also combined the advantages of real-time quantitative PCR, namely continuous fluorescent detection of PCR products with the low cost of an endpoint assay by examining in a novel manner the amount of fluorescent PCR product generated during the exponential phase of amplification. This has been achieved by using the automated loading and quantification capacity of a laser-induced fluorescence capillary electrophoresis system, the ABI Prism® 310A, so that we can effectively monitor amplification during the exponential phase cheaply, reproducibly, and in a sensitive manner. We have carefully verified our new technique using five leukemia cell lines, each expressing a different fusion transcript. Specificity and reproducibility (CV within 10%) have been examined and demonstrate the excellent precision of our technology. The high sensitivity levels of at least 10-4 to 10-60 btained for the serial dilutions of the five cell lines validate the choice of our fluorescent PCR as a comparable method to other more complicated and expensive methods. Our results have allowed us to quantify PCR products and the amount of chimeric mRNA originating from the translocation breakpoint. We demonstrate that our novel fluorescent method is useful to detect and quantify residual leukemic cells in patients undergoing therapy.
- Published
- 2002
- Full Text
- View/download PDF
3. Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania
- Author
-
J B, Robin, A, Theron, P, Quittet, C, Exbrayat, J B, Gaillard, T, Lavabre-Bertrand, S, David, A, Saad, E, Jourdan, and G, Cartron
- Subjects
Recurrence ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Leukemia, Myeloid, Chronic-Phase ,Humans ,Protein Kinase Inhibitors ,Retrospective Studies - Abstract
Tyrosine kinase inhibitor (TKI) discontinuation in chronic phase chronic myeloid leukemia (CML) patients has been examined in a real-life setting in the east occitania region of France. We have collected sex, age, prognostic scores, pre-TKI treatment, TKI length and response, relapse data from patients who had stopped TKI in prolonged complete molecular remission (CMR), and analyzed relapse risk factors. Sixty consecutive patients were included from january 2010 to december 2016. Sixteen received pre-TKI treatment. Fifty-three received a first-generation TKI, and seven had a second-generation TKI in first-line therapy. The median TKI time to achieve CMR was 20.5 months [5-137]. The median TKI length before discontinuation treatment was 73 months [12-158]. Twenty-two patients (37%) relapsed with a median time to relapse of 6 months [3-27]. An intermediate or high Sokal score was the only relapse risk factor (HR = 3.32, p 0.05) associated with relapse after TKI discontinuation. TKI discontinuation was possible without relapse for half of the patients in chronic phase CML. In a real-life cohort, a high-risk Sokal score at diagnosis appears to be an adverse prognosis feature for TKI discontinuation.
- Published
- 2020
4. 120 POMP increases proteasome assembly and activity in psoriatic lesional skin
- Author
-
T. Lavabre-Bertrand, L. Henry, Laurent Meunier, Olivier Coux, Matthieu Lacroix, P.-E. Stoebner, and B. Zieba
- Subjects
Chemistry ,Proteasome assembly ,Cell Biology ,Dermatology ,Molecular Biology ,Biochemistry ,Cell biology - Published
- 2017
- Full Text
- View/download PDF
5. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients
- Author
-
P. Möller, Carlo Bernasconi, Mario Lazzarino, Catherine Klersy, Marco Paulli, M. T. Rousset, E. Marra, J. Sträter, C. Manegold, Umberto Magrini, Umberto Gianelli, M. Gambacorta, L. Gargantini, T. Lavabre-Bertrand, and Ester Orlandi
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lymphoma, B-Cell ,Adolescent ,medicine.medical_treatment ,Gastroenterology ,Disease-Free Survival ,Risk Factors ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,B-cell lymphoma ,Survival rate ,Survival analysis ,Aged ,Neoplasm Staging ,Retrospective Studies ,Superior vena cava syndrome ,business.industry ,Mediastinum ,Thymus Neoplasms ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Lymphoma ,Surgery ,Europe ,Radiation therapy ,Treatment Outcome ,medicine.anatomical_structure ,Oncology ,Doxorubicin ,Female ,Radiotherapy, Adjuvant ,Primary mediastinal B-cell lymphoma ,medicine.symptom ,business - Abstract
PURPOSE To define clinicopathologic features, response to treatment, and prognostic factors of primary mediastinal B-cell lymphoma (MBL), a CD20+ tumor recognized as a distinct entity among non-Hodgkin's lymphomas (NHL). PATIENTS AND METHODS One hundred six patients presented with disease confined to thorax (86%), bulky mediastinum (73%), superior vena cava syndrome (47%), and contiguous infiltration (57%). Ninety-nine received doxorubicin-containing chemotherapy (CHT). RESULTS Thirty-five of 99 patients were primarily CHT-resistant, and 64 responded: 23 achieved complete response (CR) and 41 achieved response with residual mediastinal abnormality. Seventy-seven percent of responders received mediastinal radiotherapy (RT). Of 64 responders, 18 (28%) relapsed: none of 23 CR patients and 18 of 41 (44%) with residual mediastinal abnormality. Relapse-free survival rate of responders was 71% at 3 years. Actuarial 3-year survival rate was 52% for all patients and 82% for responders. Predictive factors of poor outcome were identified by logistic regression; Cox survival analysis was performed on death and relapse. Pericardial effusion (P < .001) and Eastern Cooperative Oncology Group (ECOG) performance status > or = 2 (P = .009) predicted nonresponse (NR) and affected survival. Less than partial midway response to CHT predicted NR to subsequent therapies. Bulky disease was related to persistent mediastinal abnormality and risk of relapse (P = .025). CONCLUSION MBL is an aggressive NHL with unique clinicopathologic aspects, often refractory to current CHT designed for high-grade NHL. Poor performance status and pericardial effusion predict NR and poor survival. Inadequate response after the first courses of front-line CHT predicts failure of subsequent treatment. Responders with bulky mediastinum or residual mediastinal abnormality after CHT are at risk of relapse. These factors should help to select high-risk patients for intensive treatments.
- Published
- 1997
- Full Text
- View/download PDF
6. 2. Ètude des hémopathies malignes
- Author
-
C. Brunet, T. Lavabre-Bertrand, Christine Lavabre-Bertrand, and C. Exbrayat
- Subjects
Analytical Chemistry - Published
- 1996
- Full Text
- View/download PDF
7. Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin
- Author
-
L, Henry, L, Le Gallic, G, Garcin, O, Coux, N, Jumez, P, Roger, T, Lavabre-Bertrand, J, Martinez, L, Meunier, and P E, Stoebner
- Subjects
Adult ,Aged, 80 and over ,Male ,Proteasome Endopeptidase Complex ,Arthritis, Psoriatic ,Middle Aged ,Immunohistochemistry ,Interferon-gamma ,Young Adult ,Humans ,Psoriasis ,Female ,RNA, Messenger ,Cells, Cultured ,Aged - Abstract
Deregulation of the proteasome pathway has been shown to be involved in the pathogenesis of several inflammatory disorders. To date limited information exists on proteasome and immunoproteasome expression and activity in psoriasis skin.To investigate the potential role of proteasomes in the pathogenesis of psoriasis.Thirty-six patients with psoriasis and 40 healthy subjects were included. The protein and mRNA expression levels and proteolytic activity of proteasome and immunoproteasome subunits were determined using immunohistochemistry, quantitative polymerase chain reaction and fluorogenic peptide substrate in lesional and nonlesional psoriasis skin. We additionally measured the plasmatic proteasome (p-proteasome) levels using enzyme-linked immunosorbent assay.We reveal an increased expression of proteasome and immunoproteasome subunits but stable mRNA levels in lesional psoriasis skin as compared with nonlesional psoriasis skin (n = 19), suggesting that proteasome and immunoproteasome expression is regulated post-transcriptionally. This proteasome overexpression was associated with a significant increase of the proteasomal chymotrypsin-like activity that was threefold higher in lesional skin than in nonlesional skin (n = 3). p-Proteasome levels were enhanced in patients with psoriasis (mean ± SEM 3960 ± 299 ng mL(-1) , range 1484-8987) when compared with controls (2535±187 ng mL(-1) , range 654-6446, P0·001) and were significantly higher in psoriatic arthritis (4937±572 ng mL(-1) , range 2600-8987). In addition, they were correlated to the body surface area involved and appeared thus as a new biomarker of psoriasis severity.Altogether these results strongly suggest the involvement of the proteasome system in the pathogenesis of psoriasis and support the relevance of proteasome inhibitors in local or systemic treatment of psoriasis.
- Published
- 2011
8. [Proteasome and proteasome inhibitors]
- Author
-
L, Meunier, P-E, Stoebner, M, Marque, L, Henry, J-P, Bureau, and T, Lavabre-Bertrand
- Subjects
Proteasome Endopeptidase Complex ,Ubiquitin ,Humans ,Enzyme Inhibitors ,Proteasome Inhibitors - Published
- 2005
9. L’ARNm de l’interleukine-20 est stabilisée dans la peau psoriasique lésée
- Author
-
Laurent Meunier, P.-E. Stoebner, L. Le Gallic, G. Garcin, and T. Lavabre-Bertrand
- Subjects
Dermatology - Published
- 2011
- Full Text
- View/download PDF
10. Diabetes insipidus revealing acute myelogenous leukaemia with a high platelet count, monosomy 7 and abnormalities of chromosome 3: a new entity?
- Author
-
T, Lavabre-Bertrand, P, Bourquard, J, Chiesa, M F, Berthéas, G, Lefort, J, Taïb, C, Lavabre-Bertrand, M, Navarro, and J P, Bureau
- Subjects
Adult ,Chromosome Aberrations ,Male ,Thrombocytosis ,Leukocytosis ,Platelet Count ,Translocation, Genetic ,Leukemia, Myeloid, Acute ,Fatal Outcome ,Monosomy ,Chromosome Inversion ,Humans ,Deamino Arginine Vasopressin ,Female ,Chromosomes, Human, Pair 3 ,Chromosomes, Human, Pair 7 ,Diabetes Insipidus - Abstract
We describe three cases of acute myeloid leukaemia revealed by diabetes insipidus. The patients were 42, 38 and 39 yr old and they had marked hyperleukocytosis, circulating immature granular cells and a normal or elevated platelet count. The leukaemia was type AML-M2 according to the FAB classification. Cytogenetic studies showed inversion of chromosome 3 (q21;q26) in 2 cases and a translocation (3;3)(q21;q29?) in the remaining case, both associated with monosomy 7. All the cerebral CT scans were normal. Complete remission was never achieved, and all three patients survived less than 14 months. Desmopressin therapy was active but treatment could not be reduced. The association of dysmegakaryopoiesis with a chromosome 3 abnormality and diabetes insipidus is probably not fortuitous and could represent a new entity.
- Published
- 2001
11. Spontaneous monoclonal immunoglobulin-secreting peripheral blood mononuclear cells as a marker of disease severity in multiple myeloma
- Author
-
F, Cordoba, T, Lavabre-Bertrand, S L, Salhi, M F, Huguet, J, Gerfaux, J F, Rossi, and J P, Vendrell
- Subjects
Adult ,Male ,Plasma Cells ,Enzyme-Linked Immunosorbent Assay ,Middle Aged ,Immunoglobulin Isotypes ,Disease Progression ,Leukocytes, Mononuclear ,Humans ,Female ,Waldenstrom Macroglobulinemia ,Antibody-Producing Cells ,Multiple Myeloma ,beta 2-Microglobulin ,Biomarkers ,Aged - Abstract
Peripheral blood from patients with multiple myeloma (MM) contains a small number of plasma cells related to the bone marrow tumour cells by their cytoplasmic immunoglobulin (Ig), their cell membrane antigen expression and/or their gene rearrangements, but hitherto the monoclonal Ig (M-Ig) production by circulating cells has not been reported. Using a two-colour ELISPOT assay, Ig-secreting cells (Ig-SCs) were detected in the blood of 28 MM and five Waldenstrom's macroglobulinaemia (WM) patients. The number of cells that spontaneously produced an Ig isotype similar to that of the M-Ig in serum was greater than that of the other Ig-SCs. MM patients presented an excess of circulating heavy-chain (alpha or gamma) Ig-SCs (0.38% of the PBMC) with kappa or lambda light chains (0.48%) compared with the number of cells secreting the other heavy- (0.02%) and light-chain isotypes (0.03%). WM patients also presented high numbers of cells secreting the mu-heavy-chain isotype (0.66%). The Ig synthesized in vitro was characterized as monoclonal, and the M-Ig secretory capacity of the peripheral blood cells was similar to that observed for Ig-SCs from polyclonal activated B cells in vivo. The number of these monoclonal cells was significantly increased in patients in an advanced stage of MM (I/II vs. III, P0.001) and correlated with the serum beta-2 microglobulin concentration (r = 0. 69; P0.0003). The number of M-Ig-SCs in MM patients could be a useful marker for evaluating the progression of multiple myeloma.
- Published
- 2000
12. Nephrotic syndrome associated with chronic lymphocytic leukemia resistant to immunosuppressive drugs: remission obtained by splenectomy
- Author
-
J M, Halimi, T, Lavabre-Bertrand, J J, Beraud, and B, Canaud
- Subjects
Male ,Nephrotic Syndrome ,Glomerulonephritis, Membranoproliferative ,Splenectomy ,Humans ,Middle Aged ,Leukemia, Lymphocytic, Chronic, B-Cell ,Immunosuppressive Agents - Abstract
Chronic lymphocytic leukemia is a common disease in the elderly but is rarely associated with a nephrotic syndrome. The rarity of this association suggests that leukemic cells may have certain properties or features that may lead to the development of glomerulonephritis. Effective medical treatment of the leukemia may not necessarily allow regression of the nephrotic syndrome; however, the effects of splenectomy on nephrotic proteinuria when associated to chronic lymphocytic leukemia have never been evaluated. We report the case of a 50-year-old male with stage C CD5+ chronic lymphocytic leukemia associated with a nephrotic syndrome due to Type I membranoproliferative glomerulonephritis. Chlorambucil and prednisone were unable to control the leukemia and the nephrotic range proteinuria, and were discontinued because of poor hematologic tolerance. A splenectomy immediately resulted in a spectacular remission of both chronic lymphocytic leukemia and the nephrotic syndrome. Spleen lymphocytes were collected and tested in quantitative flow cytometry for the expression of the main B cell associated markers. They did not exhibit any particular immunophenotypic pattern. This report of a remission of a glomerulonephritis associated with chronic leukemia following splenectomy is evidence of a possible relationship between the two diseases.
- Published
- 1996
13. Flow-cytometric quantitation in chronic leukemias
- Author
-
T, Lavabre-Bertrand
- Subjects
Diagnosis, Differential ,Leukemia ,Chronic Disease ,Humans ,Flow Cytometry ,Immunophenotyping - Abstract
Flow cytometric quantitation in chronic leukemias provide relevant information in different areas. It allows the characterization of additional leukemia associated parameters, like over- or under- expression as compared to normal counterparts, that is suitable for the diagnosis of malignancy or for residual disease evaluation. It improves scoring systems for the differential diagnosis between the different chronic malignancies. It allows to find original pronostic parameters and improves the comparison of different series due to a better definition of positivity. It helps to the monitoring of immune based therapeutic regimens. It provides new relevant pathophysiological informations, for instance in the study of apoptosis, as a tool for quantitative evaluation of the apoptotic process itself and for the study of its mechanism. Since its first description by Minot and Isaacs in 1924, chronic lymphocytic leukemia (CLL) has been extensively studied, due in part as it has been demonstrated as the more frequent leukemia in the Western world (Gale and Foon 1987). In addition, clinical features, cell morphology, immunological markers, histopathology and molecular genetics have been used progressively to define and characterize a wide spectrum of chronic lymphoproliferative disorders which had been previously gathered in the same entity than CLL (Benett et al., 1989, Catovsky and Matutes 1991, Harris et al., 194). Immunologic techniques are now routinely used for diagnosis in this context. Since there is no marker specific for each of these entities, scoring systems have been proposed to help diagnosis (Matutes and Catovsky 1994), which are currently investigated in multicentric studies. Flow cytometry is now widely used for immunophenotyping purposes. It allows, in addition to the determination of the percentage of positive cells, to determine the intensity of fluorescent staining, that can be converted into antigen density provided that reagents are used under saturating concentrations and correct standards of fluorescence are tested in parallel. The concept of antigen density evaluation appears to improve the efficiency of immune techniques in the monitoring of hemopoietic malignancies (Lavabre-Bertrand et al., 1994c). The present review will focus on the specific interest of immune quantitation in the study of chronic lymphoid malignancies, with a successive emphasis on diagnosis of malignancy, distinction between the different chronic lymphopathies, prognostic and therapeutic relevance, then on pathophysiological interest.
- Published
- 1996
14. Quantitative immune phenotyping: a new dimension for the monitoring of haemopoietic malignancies
- Author
-
T, Lavabre-Bertrand, F, George, C, Brunet, and J, Sampol
- Subjects
Leukemia ,Neoplasm, Residual ,Lymphoma ,Antigens, Neoplasm ,Neoplastic Stem Cells ,Humans ,Cell Differentiation ,Flow Cytometry ,Prognosis ,Immunophenotyping - Abstract
Quantitative data provided by flow cytometers are as yet not fully exploited due to the lack of standardization. However, fluorescence standardization systems are now available which allow the measurement of antigen density on a routine basis and the present review focuses on the interest of such quantitative techniques for the monitoring of haemopoietic malignancies. Antigen quantitation: (i) permits a more objective characterization of positivity, especially in the case of weakly expressed antigens; (ii) facilitates the analysis of complex populations, since certain antigens are expressed at different levels on different cell subsets; (iii) provides new data contributing to a more precise definition of cell differentiation; (iv) is of value to ascertain malignancy from the detection of aberrant antigen densities on putative neoplastic cells; (v) provides additional parameters suitable for the evaluation of residual disease and for the monitoring of immunological therapeutic regimens; (vi) contributes to prognosis. Quantitation of antigen densities should therefore be included in the routine study of haemopoietic malignancies.
- Published
- 1994
15. [Urologic manifestation of Waldenström's disease. Apropos of a case with pyelo-ureteral location]
- Author
-
M, Robert, T, Lavabre-Bertrand, J, Guiter, M, Averous, and D, Grasset
- Subjects
Male ,Humans ,Ureteral Diseases ,Kidney Diseases ,Kidney Pelvis ,Middle Aged ,Waldenstrom Macroglobulinemia - Abstract
The authors report a case of Waldenström's disease in which the initial staging assessment reveals an isolated tumour of the left upper urinary tract. Combination chemotherapy (6 courses of protocol M2) induced a marked reduction in the monoclonal IgM peak and in the tumour mass. In the light of this atypical case, which emphasises the diversity of the potential sites of Waldenström's macroglobulinaemia, the authors review its potential for progression and the various therapeutic modalities available.
- Published
- 1993
16. R49: Valeurs diagnostique, pronostique et caractérisation structurale des protéasomes plasmatiques dans le mélanome
- Author
-
Pascale Fabbro-Peray, P.E. Stoebner, Sandrine Uttenweiler-Joseph, Jean Martinez, Bernard Monsarrat, T. Lavabre-Bertrand, Thibaut Douché, L. Henry, and Laurent Meunier
- Subjects
Cancer Research ,Oncology ,Radiology, Nuclear Medicine and imaging ,Hematology ,General Medicine - Abstract
Introduction Les proteasomes plasmatiques (p-proteasomes) ou proteasomes circulants sont consideres comme des nouveaux marqueurs seriques tumoraux. Objectif Determiner les valeurs diagnostiques et pronostiques des p-proteasomes dans une population de patients atteints de melanome classee selon la classification AJCC. Methodologie Les taux de p-proteasomes etaient quantifies chez 90 patients et 40 temoins entre mars 2003 et mars 2008 avec un test ELISA. La composition des p-proteasomes etait determinee par analyse proteomique chez des patients atteints de melanome metastatique (n = 3). Resultats Les concentrations moyennes de p-proteasomes etaient correlees aux stades cliniques. Elles etaient significativement plus elevees chez les patients stade IV et stade III avec atteinte ganglionnaire (9 187 ± 1 294 et 5 091 ± 454 ng/mL, respectivement) comparativement aux temoins (2 535 ± 187 ng/mL, p 4 300 ng/mL) etaient significativement correles a un risque accru de progression (HR = 7,34, IC 95 % 3,54 a 15,21).
- Published
- 2010
- Full Text
- View/download PDF
17. [Cancer of the testis after Hodgkin's disease. Apropos of 2 cases]
- Author
-
M, Robert, M, Averous, T, Lavabre-Bertrand, F, Iborra, P, Chevallier, X, Rebillard, J, Guiter, and D, Grasset
- Subjects
Adult ,Male ,Neoplasms, Radiation-Induced ,Teratoma ,Dysgerminoma ,Vinblastine ,Hodgkin Disease ,Dacarbazine ,Bleomycin ,Testicular Neoplasms ,Doxorubicin ,Vincristine ,Procarbazine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Prednisone ,Mechlorethamine ,Orchiectomy - Abstract
We report about two cases of cancer of the testis occurring 2 and 7 years after Hodgkin's disease treated with combined chemotherapy and radiation therapy. From an etiopathogenic point of view, this association may, of course, be accidental, but it may also have an iatrogenic origin or be caused by contiguous carcinogenesis, or even by an immune deficiency. In addition to orchidectomy, the therapeutic history of these patients requires an adaptation of the treatment of their tumors of the testes.
- Published
- 1992
18. Lymphome primitif du rein
- Author
-
J.M. Bruel, F. Blanc, J. Guiter, E. Vaucher, E. Monnin, P. Baldet, P. Blanc, T. Lavabre-Bertrand, and V. Trussart
- Subjects
business.industry ,Gastroenterology ,Internal Medicine ,Medicine ,business ,Humanities - Published
- 1989
- Full Text
- View/download PDF
19. Acute monocytic leukemia with B cell markers expression following B chronic lymphocytic leukemia
- Author
-
T, Lavabre-Bertrand, D, Donadio, A, Breton, J, Taib, D, Charlier, C, Assens, P, Poncelet, B, Murgue, J P, Vendrell, and J M, Emberger
- Subjects
Male ,B-Lymphocytes ,Leukocyte Count ,Phenotype ,Platelet Count ,Leukemia, Monocytic, Acute ,Humans ,Chlorambucil ,Leukemia, Lymphocytic, Chronic, B-Cell ,Aged - Abstract
A case of chronic lymphocytic leukemia (CLL) treated with chlorambucil, followed by the development of an acute monoblastic leukemia, is described. Cytofluorometric quantitative immunophenotype was determined during the blastic phase. Whereas small lymphocytes displayed a CD19+; CD24+; CD37+; CD5+ phenotype, the blastic population exhibited, besides CD13, CD14 and CD15 positivity, which is usually noted in such a monoblastic leukemia, definite CD9, CD10, CD22, CD24, CD37, CD5 and CD4 staining. Such results argue against a complete independence between the two clones, although their similarity could not be demonstrated.
- Published
- 1989
20. [Chronic herpes of the pyodermatitis vegetans type in chronic cutaneous lymphoid leukemia]
- Author
-
L, Meunier, B, Guillot, T, Lavabre-Bertrand, G, Barnéon, P, Izarn, and J, Meynadier
- Subjects
Male ,B-Lymphocytes ,Skin Neoplasms ,Pyoderma ,Chronic Disease ,Immune Tolerance ,Acyclovir ,Humans ,Herpes Simplex ,Facial Dermatoses ,Aged ,Leukemia, Lymphoid - Abstract
The authors report a case of chronic herpes virus infection of the face which developed in a 70-year old man already affected with chronic lymphocytic leukaemia of the B-cell type (CLL-B) with specific cutaneous localisations. Immunodepression was indicated only by marked hypogammaglobulinaemia. Cell-mediated immunity was preserved. The cutaneous lesions of the face were chronic and presented as pyodermatitis vegetans. A one-week course of acyclovir administered by intravenous infusion in doses of 5 mg/kg three times a day resulted in rapid and dramatic cure, but this result proved transient, since the virus infection relapsed 2 1/2 months later. The new episode also was successfully treated with a second course of acyclovir. The herpes virus infection had developed only on those skin areas that were specifically affected by the leukaemia; after treatment and eradication of the virus, massive lymphocytic infiltration of the dermis persisted in these areas. Involvement of the skin is rare in CLL-B and has been reported mainly in CLL-T. The lesions most frequently encountered are tuberous and papular lesions and infiltrated plaques on the forehead and ears. The pyodermatitis vegetans presentation is unusual. The reasons why viral skin lesions develop on those caused by leukaemia are unknown.
- Published
- 1986
21. [Primary lymphoma of the kidney. Review of the literature apropos of a case]
- Author
-
P, Blanc, T, Lavabre-Bertrand, E, Vaucher, E, Monnin, J, Guiter, P, Baldet, V, Trussart, J M, Bruel, and F, Blanc
- Subjects
Lymphoma, Non-Hodgkin ,Humans ,Female ,Middle Aged ,Kidney Neoplasms - Published
- 1989
22. Primary mediastinal B-Cell lymphoma: Update of its clinicopathologic features
- Author
-
Ester Orlandi, Manegold C, Catherine Klersy, Marco Paulli, Sträter E, Carlo Bernasconi, Peter Möller, Rousset T, T. Lavabre-Bertrand, Alessandra Viglio, Marcello Gambacorta, Morra E, Umberto Magrini, Umberto Gianelli, R. Rosso, and M. Lazzarino
- Subjects
Cancer Research ,medicine.medical_specialty ,Pathology ,Lymphoma, B-Cell ,business.industry ,Mediastinum ,Hematology ,Prognosis ,medicine.disease ,Mediastinal Neoplasms ,Lymphoma ,Radiography ,Treatment Outcome ,medicine.anatomical_structure ,Oncology ,Biomarkers, Tumor ,Humans ,Medicine ,Primary mediastinal B-cell lymphoma ,Radiology ,business ,B cell - Abstract
The peculiar clinical, histomorphological and biological characteristics of PMBCL are reviewed. Special emphasis is given to the frequent aggressive clinical behaviour of this lymphoma in which conventional prognostic factors seem inadequate to identify high risk cases. The need for new clinical and/or biological prognostic markers is stressed.
23. FAMILIAL PSEUDOHYPERKALÆMIA
- Author
-
J.-C. Luciani, A. Mimran, T. Lavabre-Bertrand, P. Barjon, A. Callis, and J. Fourcade
- Subjects
Chemistry ,General Medicine - Published
- 1980
- Full Text
- View/download PDF
24. EGLN1 mutations in Cis can induce congenital erythrocytosis with thromboses by increasing protein instability.
- Author
-
Carillo S, Delamare M, Henry L, Maaziz N, Safraou H, Gardie B, and Lavabre-Bertrand T
- Subjects
- Humans, Female, Male, Pedigree, Mutation, Adult, Mutation, Missense, Polycythemia genetics, Polycythemia congenital, Hypoxia-Inducible Factor-Proline Dioxygenases genetics, Protein Stability
- Abstract
Hereditary congenital erythrocytosis results from constitutive activation of the hypoxia pathway. This pathway is controlled by regulation of the α isoforms of the hypoxia-inducible factor α/β heterodimer, notably via hydroxylation by prolyl hydroxylase domain 2 (PHD2). Mutations affecting PHD2 are involved in Type 3 erythrocytosis. We report an atypical family bearing two PHD2 mutations located in Cis (L195H and E225D) transmitted in a dominant feature, together with a phenotypic analysis, structural modelling and functional study. Mutations have a cumulative effect, with E255D playing the major role, and severely compromised PHD2 stability, probably explaining why the hypoxia pathway at the origin of the disease is activated., (© 2025 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2025
- Full Text
- View/download PDF
25. Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.
- Author
-
Bonnet S, Carillo S, Legrand B, Burroni B, Lavabre-Bertrand T, Requirand G, Robert N, Fornero L, Al Mansoori A, Moreaux J, Cartron G, Gabellier L, and Herbaux C
- Subjects
- Humans, Calreticulin genetics, Calreticulin metabolism, Mutation, Exons, Janus Kinase 2 genetics, Thrombocytosis diagnosis, Primary Myelofibrosis genetics, Myelodysplastic-Myeloproliferative Diseases complications, Myeloproliferative Disorders genetics
- Abstract
We describe the case of a patient with extreme thrombocytosis whose evolution was rapidly fatal. No cause of secondary thrombocytosis was found. There was no sign of myelofibrosis but the megakaryocytes were small and dysplastic. The patient presented a calreticulin (CALR) variant in exon 3 (C105S), as well as concomitant mutations of ASXL1, U2AF1, and EZH2. This variant of CALR has never been described before, and after sorting, all identified mutations were found in myeloid cells but not in lymphoid cells. Therefore, the diagnosis of a frontier case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) was made. A treatment with hydroxycarbamide was started because of a high risk of thrombosis. Upon worsening of the hematological status two new mutations appeared, SETBP1 and ETV6, and the CALR mutation was still detectable, as well as the three other mutations found in the chronic stage. Our results show that this variant could contribute to MDS/MPN pathogenesis in that patient., (© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
26. The discovery of hypoglycaemic sulphonamides - Montpellier, 1942.
- Author
-
Lavabre-Bertrand T and Faillie JL
- Subjects
- Humans, Hypoglycemic Agents, Insulin, Male, Sulfonamides, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypoglycemia
- Abstract
The pathophysiological study of diabetes mellitus took an important place in the school of Montpellier since the end of the XIX
th century with Emmanuel Hedon's (1863-1933) contribution to the demonstration of the endocrine function of the pancreas. In 1942, a new sulfonamide compound (2254RP) was tested in the infectious diseases department of Pr M. Janbon (1898-1996) on cases of typhoid fever, leading to several deaths rapidly related to hypoglycaemia. The physiologist Auguste Loubatières (1912-1977) rapidly demonstrated that this hypoglycaemic effect required the presence of pancreas and was explained by stimulation of insulin secretion. He contributed to the description of a hypoglycaemic effect of several other sulphonamide compounds. He considered the diagnostic and therapeutic relevance of this class of drugs. This is a good example of a medical discovery combining a favourable local environment, serendipity and perfect experimental approach., (Copyright © 2021 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
27. A +3 variant at a donor splice site leads to a skipping of the MYH11 exon 32, a recurrent RNA defect causing Heritable Thoracic Aortic Aneurysm and Dissection and/or Patent Ductus Arteriosus.
- Author
-
Chesneau B, Plancke A, Rolland G, Marcheix B, Dulac Y, Edouard T, Plaisancié J, Aubert-Mucca M, Julia S, Langeois M, Lavabre-Bertrand T, and Khau Van Kien P
- Subjects
- Aortic Dissection pathology, Aortic Aneurysm, Thoracic pathology, Ductus Arteriosus, Patent pathology, Exons, Humans, Male, Mutation, RNA Splicing, Young Adult, Aortic Dissection genetics, Aortic Aneurysm, Thoracic genetics, Ductus Arteriosus, Patent genetics, Myosin Heavy Chains genetics, RNA Splice Sites
- Abstract
Background: Pathogenic variants in MYH11 are associated with either heritable thoracic aortic aneurysm and dissection (HTAAD), patent ductus arteriosus (PDA) syndrome, or megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)., Methods and Results: We report a family referred for molecular diagnosis with HTAAD/PDA phenotype in which we found a variant at a non-conserved position of the 5' donor splice site of intron 32 of MYH11 potentially altering splicing (NM_002474.3:c.4578+3A>C). Although its cosegregation with disease was observed, it remained of unknown significance. Later, aortic surgery in the proband gave us the opportunity to perform a transcript analysis. This showed a skipping of the exon 32, an RNA defect previously reported to be translated to an in-frame loss of 71 amino acids and a dominant-negative effect in the smooth muscle myosin rod. This RNA defect is also reported in 3 other HTAAD/PDA pedigrees., Conclusion: This report confirms that among rare variants in MYH11, skipping of exon 32 is recurrent. This finding is of particular interest to establish complex genotype-phenotype correlations where some alleles are associated with autosomal dominant HTAAD/PDA, while others result in recessive or dominant visceral myopathies., (© 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
28. Parental mosaicism in Marfan and Ehlers-Danlos syndromes and related disorders.
- Author
-
Chesneau B, Plancke A, Rolland G, Chassaing N, Coubes C, Brischoux-Boucher E, Edouard T, Dulac Y, Aubert-Mucca M, Lavabre-Bertrand T, Plaisancié J, and Khau Van Kien P
- Subjects
- Adult, Aged, Child, Collagen Type V genetics, Ehlers-Danlos Syndrome pathology, Female, Fibrillin-1 genetics, Genetic Testing methods, Humans, Male, Marfan Syndrome pathology, Middle Aged, Pedigree, Ehlers-Danlos Syndrome genetics, Marfan Syndrome genetics, Mosaicism
- Abstract
Marfan syndrome (MFS) is a heritable connective tissue disorder (HCTD) caused by pathogenic variants in FBN1 that frequently occur de novo. Although individuals with somatogonadal mosaicisms have been reported with respect to MFS and other HCTD, the overall frequency of parental mosaicism in this pathology is unknown. In an attempt to estimate this frequency, we reviewed all the 333 patients with a disease-causing variant in FBN1. We then used direct sequencing, combined with High Resolution Melting Analysis, to detect mosaicism in their parents, complemented by NGS when a mosaicism was objectivized. We found that (1) the number of apparently de novo events is much higher than the classically admitted number (around 50% of patients and not 25% as expected for FBN1) and (2) around 5% of the FBN1 disease-causing variants were not actually de novo as anticipated, but inherited in a context of somatogonadal mosaicisms revealed in parents from three families. High Resolution Melting Analysis and NGS were more efficient at detecting and evaluating the level of mosaicism compared to direct Sanger sequencing. We also investigated individuals with a causal variant in another gene identified through our "aortic diseases genes" NGS panel and report, for the first time, on an individual with a somatogonadal mosaicism in COL5A1. Our study shows that parental mosaicism is not that rare in Marfan syndrome and should be investigated with appropriate methods given its implications in patient's management.
- Published
- 2021
- Full Text
- View/download PDF
29. The teaching of anatomy in Montpellier University during VIII centuries (1220-2020).
- Author
-
Bonnel F, Lavabre-Bertrand T, and Bonnel C
- Subjects
- Anatomy history, Cadaver, Dissection history, France, History, 15th Century, History, 16th Century, History, 17th Century, History, 18th Century, History, 19th Century, History, 20th Century, History, 21st Century, History, Medieval, Humans, Models, Anatomic, Anatomy education, Teaching history, Universities history
- Abstract
Since 1220 in Montpellier the human cadaver dissection had been used for the teaching of anatomy. In the first time the anatomy was based on animal knowledge. Vesalius student in Montpellier then in Italy, written the first book on human anatomy. Among teachers some of them made discoveries such as Pecquet on cisterna chyli, Vieussens on brain and hearth. Wax anatomy was used for teaching and Laumonier and B. Delmas presented some very nice pieces. Progressively a lot of anatomical preparations were exposed in a conservatory with 2330 human cadavers' dissections obtained during a lot of examinations. Anatomy and pathology were developed by Delpech about growing of bones with laws. In 1953 two anatomist surgeons, Rapp and Couinaud, described the segmentation of the liver with using techniques of corrosion. In the conservatory 250 corrosions of the livers are exposed, this is certainly the most numerous in the world and it represents a huge basis for surgery and liver transplantation. Since 1900 the teaching of anatomy continued with blackboard lectures and Human cadavers dissections. Therefore, a new approach of anatomy with computer is going to be used in the future.
- Published
- 2019
- Full Text
- View/download PDF
30. Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations.
- Author
-
Lodé L, Ameur A, Coste T, Ménard A, Richebourg S, Gaillard JB, Le Bris Y, Béné MC, Lavabre-Bertrand T, and Soussi T
- Subjects
- Alleles, Genetic Association Studies, Genetic Predisposition to Disease, High-Throughput Nucleotide Sequencing, Humans, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute therapy, Mutation, Myelodysplastic Syndromes mortality, Myelodysplastic Syndromes pathology, Myelodysplastic Syndromes therapy, Prognosis, Sequence Analysis, DNA, Genetic Variation, Leukemia, Myeloid, Acute genetics, Myelodysplastic Syndromes genetics, Tumor Suppressor Protein p53 genetics
- Published
- 2018
- Full Text
- View/download PDF
31. The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin.
- Author
-
Zieba BA, Henry L, Lacroix M, Jemaà M, Lavabre-Bertrand T, Meunier L, Coux O, and Stoebner PE
- Subjects
- Apoptosis, Biopsy, Blotting, Western, Cell Differentiation, Cell Line, Cell Proliferation, Cytoplasm, Epidermal Cells, Epidermis pathology, Humans, Keratinocytes metabolism, Molecular Chaperones genetics, Native Polyacrylamide Gel Electrophoresis, RNA Interference, RNA, Small Interfering metabolism, Keratinocytes pathology, Molecular Chaperones metabolism, Proteasome Endopeptidase Complex metabolism, Psoriasis pathology, RNA, Messenger metabolism
- Abstract
Background: The ubiquitin proteasome pathway is involved in the pathogenesis of psoriasis and proteasome subunits are increased in lesional psoriatic skin. Recent works have highlighted that proteasome levels can be regulated through modulation of proteasome assembly notably by the proteasome maturation protein POMP., Objectives: To investigate whether proteasome assembly and POMP expression are modified in psoriatic skin., Methods: Proteasome assembly as well as expression of proteasome regulators were assessed in non-lesional and lesional psoriatic skin using native gel electrophoresis and western blots respectively. The protein and mRNA expression levels of POMP were compared by western blots, immunohistochemistry and quantitative polymerase chain reaction. The role of POMP in keratinocyte proliferation and differentiation was assessed by silencing POMP gene expression by RNA interference in human immortalized keratinocyte HaCaT cells., Results: Both 20S and 26S proteasomes (and their respective proteolytic activities) as well as the main proteasome regulators are increased in lesional psoriatic skin. POMP binds to 20S precursor complexes and is overexpressed in lesional epidermal psoriatic skin, supporting that POMP-mediated proteasome assembly is increased in psoriatic skin. POMP silencing inhibited HaCaT cell proliferation and induced apoptosis through the inhibition of the proteasome assembly. Moreover POMP partial depletion decreased the expression of the differentiation markers keratin 10 and involucrin during the [Ca
2+ ]-induced HaCaT cells differentiation., Conclusion: Altogether these results establish a potential role for POMP and proteasome assembly in psoriasis pathogenesis., (Copyright © 2017 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
32. Gene editing rescue of a novel MPL mutant associated with congenital amegakaryocytic thrombocytopenia.
- Author
-
Cleyrat C, Girard R, Choi EH, Jeziorski É, Lavabre-Bertrand T, Hermouet S, Carillo S, and Wilson BS
- Abstract
Thrombopoietin (Tpo) and its receptor (Mpl) are the principal regulators of early and late thrombopoiesis and hematopoietic stem cell maintenance. Mutations in MPL can drastically impair its function and be a contributing factor in multiple hematologic malignancies, including congenital amegakaryocytic thrombocytopenia (CAMT). CAMT is characterized by severe thrombocytopenia at birth, which progresses to bone marrow failure and pancytopenia. Here we report unique familial cases of CAMT that presented with a previously unreported MPL mutation: T814C (W272R) in the background of the activating MPL G117T (K39N or Baltimore) mutation. Confocal microscopy, proliferation and surface biotinylation assays, co-immunoprecipitation, and western blotting analysis were used to elucidate the function and trafficking of Mpl mutants. Results showed that Mpl protein bearing the W272R mutation, alone or together with the K39N mutation, lacks detectable surface expression while being strongly colocalized with the endoplasmic reticulum (ER) marker calreticulin. Both WT and K39N-mutated Mpl were found to be signaling competent, but single or double mutants bearing W272R were unresponsive to Tpo. Function of the deficient Mpl receptor could be rescued by using 2 separate approaches: (1) GRASP55 overexpression, which partially restored Tpo-induced signaling of mutant Mpl by activating an autophagy-dependent secretory pathway and thus forcing ER-trapped immature receptors to traffic to the cell surface; and (2) CRISPR-Cas9 gene editing used to repair MPL T814C mutation in transfected cell lines and primary umbilical cord blood-derived CD34
+ cells. We demonstrate proof of principle for rescue of mutant Mpl function by using gene editing of primary hematopoietic stem cells, which indicates direct therapeutic applications for CAMT patients., Competing Interests: Conflict-of-interest disclosure: The authors declare no competing financial interests.- Published
- 2017
- Full Text
- View/download PDF
33. Long non-coding RNAs in human early embryonic development and their potential in ART.
- Author
-
Bouckenheimer J, Assou S, Riquier S, Hou C, Philippe N, Sansac C, Lavabre-Bertrand T, Commes T, Lemaître JM, Boureux A, and De Vos J
- Subjects
- Humans, Neoplasms genetics, X Chromosome Inactivation, Embryonic Development genetics, Gene Expression Regulation, RNA, Long Noncoding metabolism
- Abstract
Background: Human long non-coding RNAs (lncRNAs) are an emerging category of transcripts with increasingly documented functional roles during development. LncRNAs and roles during human early embryo development have recently begun to be unravelled., Objective and Rationale: This review summarizes the most recent knowledge on lncRNAs and focuses on their expression patterns and role during early human embryo development and in pluripotent stem cells (PSCs). Public mRNA sequencing (mRNA-seq) data were used to illustrate these expression signatures., Search Methods: The PubMed and EMBASE databases were first interrogated using specific terms, such as 'lncRNAs', to get an extensive overview on lncRNAs up to February 2016, and then using 'human lncRNAs' and 'embryo', 'development', or 'PSCs' to focus on lncRNAs involved in human embryo development or in PSC.Recently published RNA-seq data from human oocytes and pre-implantation embryos (including single-cell data), PSC and a panel of normal and malignant adult tissues were used to describe the specific expression patterns of some lncRNAs in early human embryos., Outcomes: The existence and the crucial role of lncRNAs in many important biological phenomena in each branch of the life tree are now well documented. The number of identified lncRNAs is rapidly increasing and has already outnumbered that of protein-coding genes. Unlike small non-coding RNAs, a variety of mechanisms of action have been proposed for lncRNAs. The functional role of lncRNAs has been demonstrated in many biological and developmental processes, including cell pluripotency induction, X-inactivation or gene imprinting. Analysis of RNA-seq data highlights that lncRNA abundance changes significantly during human early embryonic development. This suggests that lncRNAs could represent candidate biomarkers for developing non-invasive tests for oocyte or embryo quality. Finally, some of these lncRNAs are also expressed in human cancer tissues, suggesting that reactivation of an embryonic lncRNA program may contribute to human malignancies., Wider Implications: LncRNAs are emerging potential key players in gene expression regulation. Analysis of RNA-seq data from human pre-implantation embryos identified lncRNA signatures that are specific to this critical step. We anticipate that further studies will show that these new transcripts are major regulators of embryo development. These findings might also be used to develop new tests/treatments for improving the pregnancy success rate in IVF procedures or for regenerative medicine applications involving PSC., (© The Author 2016. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
34. AMPK/HuR-Driven IL-20 Post-Transcriptional Regulation in Psoriatic Skin.
- Author
-
Garcin G, Guiraud I, Lacroix M, Genthon C, Rialle S, Joujoux JM, Meunier L, Lavabre-Bertrand T, Stoebner PE, and Le Gallic L
- Subjects
- AMP-Activated Protein Kinases genetics, Animals, Biopsy, Needle, Cells, Cultured, Disease Models, Animal, ELAV-Like Protein 1 genetics, Humans, Immunohistochemistry, Keratinocytes cytology, Keratinocytes metabolism, Mice, Mice, Inbred C57BL, RNA Interference, RNA, Messenger genetics, Random Allocation, Real-Time Polymerase Chain Reaction methods, Skin cytology, Skin pathology, Statistics, Nonparametric, Up-Regulation, AMP-Activated Protein Kinases metabolism, ELAV-Like Protein 1 metabolism, Gene Expression Regulation, Interleukins genetics, Psoriasis genetics, Psoriasis pathology
- Abstract
IL-20 is involved in the development of skin psoriasis. The molecular mechanisms underlying IL-20 overexpression in psoriatic epidermis remain to be elucidated. We showed that IL-20 was primarily upregulated in psoriatic skin at the post-transcriptional level. The RNA-binding protein HuR relocalized to the cytoplasm of keratinocytes (KCs) of psoriatic patients, suggesting that it stabilizes numerous transcripts, as observed in the human KC cell lines used to assess IL-20 mRNA. We characterized epidermal HuR RNA targets in psoriatic skin using ribonucleoprotein immunoprecipitation analyzed via high-throughput sequencing. Numerous transcripts that are upregulated in psoriasis were targeted by HuR, supporting the participation of HuR in pathogenic processes such as morphological changes, innate and adaptive immune responses, and metabolic inflammatory responses. Finally, we identified the metabolic sensor AMP-activated protein kinase (AMPK) as being responsible for HuR cytoplasmic relocalization because its activity was severely impaired in human psoriatic epidermis, and in vivo drug-mediated AMPK inhibition in mouse epidermis promoted HuR cytoplasmic localization, IL-20 overproduction, acanthosis, and hyperkeratosis. These results provide insights into the molecular links between metabolism and post-transcriptional networks during chronic inflammation.
- Published
- 2015
- Full Text
- View/download PDF
35. Temporal analysis of genome alterations induced by single-cell passaging in human embryonic stem cells.
- Author
-
Bai Q, Ramirez JM, Becker F, Pantesco V, Lavabre-Bertrand T, Hovatta O, Lemaître JM, Pellestor F, and De Vos J
- Subjects
- Abnormal Karyotype, Cell Line, Cell Proliferation, DNA Breaks, Double-Stranded, Gene Expression, Genome, Human, Humans, Human Embryonic Stem Cells physiology
- Abstract
Simplified culture conditions are essential for large-scale drug screening and medical applications of human pluripotent stem cells (hPSCs). However, hPSCs [ie, human embryonic stem cells (hESCs), and human induced pluripotent stem cells (iPSCs) are prone to genomic instability, a phenomenon that is highly influenced by the culture conditions. Enzymatic dissociation, a cornerstone of large-scale hPSC culture systems, has been reported to be deleterious, but the extent and the timeline of the genomic alterations induced by this passaging technique are still unclear. We prospectively monitored three hESC lines that were initially derived and cultured on human feeders and passaged mechanically before switching to enzymatic single-cell passaging. We show that karyotype abnormalities and copy number variations are not restricted to long-term culture, but can occur very rapidly, within five passages after switching hESCs to enzymatic dissociation. Subchromosomal abnormalities preceded or accompanied karyotype abnormalities and were associated with increased occurrence of DNA double-strand breaks. Our results indicate that enzymatic single-cell passaging can be highly deleterious to the hPSC genome, even when used only for a limited period of time. Moreover, hPSC culture techniques should be reappraised by complementing the routine karyotype analysis with more sensitive techniques, such as microarrays, to detect subchromosomal abnormalities.
- Published
- 2015
- Full Text
- View/download PDF
36. [Louis Vialleton (1859-1929) was the first Professor of Histology in the Faculty of medicine of Montpellier].
- Author
-
Lavabre-Bertrand T
- Subjects
- France, History, 19th Century, History, 20th Century, Humans, Education, Medical history, Faculty, Medical history, Histology history
- Abstract
Dean for few years, he mainly focused his research on a precise criticism of transformism, which began to represent the common explanation of the emergence of life and species. For him, no classical argument in favour of this theory could be retained when considering Morphology as a complete association of structure and function in the whole animal. Beyond some aspects of this criticism related to his time, Vialleton transcends them by his conception of Morphology as an incarnated "platonician idea", that inserts him in the fliation of Montpellier vitalism.
- Published
- 2015
37. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
- Author
-
Henry L, Fabre C, Guiraud I, Bastide S, Fabbro-Peray P, Martinez J, Lavabre-Bertrand T, Meunier L, and Stoebner PE
- Subjects
- Adult, Aged, Aged, 80 and over, Colorimetry, Enzyme-Linked Immunosorbent Assay, Female, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis, Male, Melanoma blood, Melanoma secondary, Middle Aged, Neoplasm Staging, Plasma, Predictive Value of Tests, Prognosis, Proportional Hazards Models, S100 Calcium Binding Protein beta Subunit, Skin Neoplasms blood, Skin Neoplasms pathology, Biomarkers, Tumor blood, Extracellular Matrix Proteins blood, L-Lactate Dehydrogenase blood, Melanoma diagnosis, Neoplasm Proteins blood, Nerve Growth Factors blood, Proteasome Endopeptidase Complex blood, S100 Proteins blood, Skin Neoplasms diagnosis
- Abstract
Plasmatic proteasome (p-proteasome) has recently been described as a new marker for metastatic melanoma. The objective of this study was to compare the diagnostic and prognostic values of p-proteasome with three other melanoma serological markers: S100B protein, melanoma inhibitory activity protein (MIA) and lactate dehydrogenase (LDH) in the plasma of 121 stage I-IV melanoma patients. Laboratory analyses were performed by standardized ELISA (p-proteasome, MIA), immunoluminometric assay (S100B) and colorimetry (LDH). We found that all markers were relevant for discriminating metastatic from nonmetastatic patients but p-proteasome displayed the highest diagnostic accuracy. P-proteasome and S100B were the most sensitive (58.1%) and p-proteasome and MIA the most specific (98.7 and 100%) in detecting metastatic disease. P-proteasome and S100B had the highest area under receiver operating characteristics curve, 0.811 (95% CI: 0.725-0.897) and 0.822 (95% CI: 0.738-0.906), respectively. These two markers were the best in detecting patients with lymph node metastases. S100B, MIA and LDH diagnostic accuracy was increased when these markers were combined with p-proteasome. As shown with univariate analysis, shorter progression-free and overall survival rates were significantly associated with elevated plasma levels of each markers. The multivariate Cox regression analysis identified p-proteasome as the only independent predictor of a poorer progression-free survival (p = 0.030). In conclusion, this comparative study established that p-proteasome quantification in combination with other melanoma biomarkers is an attractive approach for the biological follow-up of melanoma patients., (Copyright © 2012 UICC.)
- Published
- 2013
- Full Text
- View/download PDF
38. Association of myeloproliferative and lymphoproliferative disorders.
- Author
-
Gaillard JB, Carillo S, Henry L, Jourdan E, and Lavabre-Bertrand T
- Subjects
- Biopsy, Bone Marrow pathology, Female, Humans, Lymphoproliferative Disorders diagnosis, Male, Middle Aged, Myeloproliferative Disorders diagnosis, Pedigree, Lymphoproliferative Disorders complications, Myeloproliferative Disorders complications
- Published
- 2012
39. New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients.
- Author
-
Bou Samra E, Moreaux J, Vacheret F, Mills K, Rufflé F, Chiesa J, Piquemal D, Boureux A, Lavabre-Bertrand T, Jourdan E, and Commes T
- Subjects
- Aged, Aged, 80 and over, Case-Control Studies, Female, Follow-Up Studies, Gene Expression Profiling methods, Humans, Kaplan-Meier Estimate, Leukemia, Myelomonocytic, Chronic therapy, Male, Middle Aged, Multigene Family, Oligonucleotide Array Sequence Analysis methods, Polymerase Chain Reaction methods, Prognosis, RNA, Neoplasm genetics, Treatment Outcome, U937 Cells, Biomarkers, Tumor metabolism, Leukemia, Myelomonocytic, Chronic diagnosis
- Abstract
Chronic myelomonocytic leukaemia (CMML) is a heterogeneous haematopoietic disorder characterized by myeloproliferative or myelodysplastic features. At present, the pathogenesis of this malignancy is not completely understood. In this study, we sought to analyse gene expression profiles of CMML in order to characterize new molecular outcome predictors. A learning set of 32 untreated CMML patients at diagnosis was available for TaqMan low-density array gene expression analysis. From 93 selected genes related to cancer and cell cycle, we built a five-gene prognostic index after multiplicity correction. Using this index, we characterized two categories of patients with distinct overall survival (94% vs. 19% for good and poor overall survival, respectively; P = 0·007) and we successfully validated its strength on an independent cohort of 21 CMML patients with Affymetrix gene expression data. We found no specific patterns of association with traditional prognostic stratification parameters in the learning cohort. However, the poor survival group strongly correlated with high-risk treated patients and transformation to acute myeloid leukaemia. We report here a new multigene prognostic index for CMML, independent of the gene expression measurement method, which could be used as a powerful tool to predict clinical outcome and help physicians to evaluate criteria for treatments., (© 2012 Blackwell Publishing Ltd.)
- Published
- 2012
- Full Text
- View/download PDF
40. Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion.
- Author
-
Gaillard JB, Chiesa J, Reboul D, Arnaud A, Brun S, Donadio D, Exbrayat C, Wickenhauser S, Bourquard P, Jourdan E, and Lavabre-Bertrand T
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, In Situ Hybridization, Fluorescence, Karyotyping, Male, Middle Aged, Prognosis, Young Adult, Abnormal Karyotype, Gene Deletion, Leukemia, Myeloid, Acute genetics, Monosomy, Tumor Suppressor Protein p53 genetics
- Published
- 2012
- Full Text
- View/download PDF
41. Proteolytic activity and expression of the 20S proteasome are increased in psoriasis lesional skin.
- Author
-
Henry L, Le Gallic L, Garcin G, Coux O, Jumez N, Roger P, Lavabre-Bertrand T, Martinez J, Meunier L, and Stoebner PE
- Subjects
- Adult, Aged, Aged, 80 and over, Arthritis, Psoriatic enzymology, Cells, Cultured, Female, Humans, Immunohistochemistry, Interferon-gamma pharmacology, Male, Middle Aged, RNA, Messenger metabolism, Young Adult, Proteasome Endopeptidase Complex metabolism, Psoriasis enzymology
- Abstract
Background: Deregulation of the proteasome pathway has been shown to be involved in the pathogenesis of several inflammatory disorders. To date limited information exists on proteasome and immunoproteasome expression and activity in psoriasis skin., Objectives: To investigate the potential role of proteasomes in the pathogenesis of psoriasis., Methods: Thirty-six patients with psoriasis and 40 healthy subjects were included. The protein and mRNA expression levels and proteolytic activity of proteasome and immunoproteasome subunits were determined using immunohistochemistry, quantitative polymerase chain reaction and fluorogenic peptide substrate in lesional and nonlesional psoriasis skin. We additionally measured the plasmatic proteasome (p-proteasome) levels using enzyme-linked immunosorbent assay., Results: We reveal an increased expression of proteasome and immunoproteasome subunits but stable mRNA levels in lesional psoriasis skin as compared with nonlesional psoriasis skin (n = 19), suggesting that proteasome and immunoproteasome expression is regulated post-transcriptionally. This proteasome overexpression was associated with a significant increase of the proteasomal chymotrypsin-like activity that was threefold higher in lesional skin than in nonlesional skin (n = 3). p-Proteasome levels were enhanced in patients with psoriasis (mean ± SEM 3960 ± 299 ng mL(-1) , range 1484-8987) when compared with controls (2535±187 ng mL(-1) , range 654-6446, P<0·001) and were significantly higher in psoriatic arthritis (4937±572 ng mL(-1) , range 2600-8987). In addition, they were correlated to the body surface area involved and appeared thus as a new biomarker of psoriasis severity., Conclusions: Altogether these results strongly suggest the involvement of the proteasome system in the pathogenesis of psoriasis and support the relevance of proteasome inhibitors in local or systemic treatment of psoriasis., (© 2011 The Authors. BJD © 2011 British Association of Dermatologists 2011.)
- Published
- 2011
- Full Text
- View/download PDF
42. Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia.
- Author
-
Carillo S, Henry L, Lippert E, Girodon F, Guiraud I, Richard C, Dubois Galopin F, Cleyrat C, Jourdan E, Kralovics R, Hermouet S, and Lavabre-Bertrand T
- Subjects
- Adult, Aged, Aged, 80 and over, Base Sequence, Female, Humans, Male, Middle Aged, Reproducibility of Results, Sensitivity and Specificity, Young Adult, Exons, Genetic Techniques, Janus Kinase 2 genetics, Mutation genetics, Polycythemia Vera diagnosis, Polycythemia Vera genetics, Polymerase Chain Reaction
- Abstract
JAK2 exon 12 mutations are found in myeloproliferative disorders characterized by erythrocytosis. Lying in a 33-bp region and conserving the open reading frame, they often present a low allelic burden (<10%), which excludes screening with techniques such as allele-specific PCR or different sequencing protocols. High-resolution melting (HRM), a fast in-tube method, seems the most accurate routine technique for that. We describe a reliable and powerful nested HRM technique, independent of DNA preparation and with technical sensitivity of 100% (95% CI, 93% to 100%) and specificity of 96.7% (95% CI, 89.7% to 96.7%). Screening a cohort of 10 idiopathic erythrocytosis, 28 polycythemia vera, and 7 secondary erythrocytosis cases allowed the detection of 15 mutants, including 9 different mutations, of which 3 were unreported, all in the polycythemia vera group, and presented a characteristic profile: pure erythrocytosis associated with low serum erythropoietin. Threshold detection level ranged from 1% to 3% allelic burden, depending on the mutation. All of the HRM positive signals were found mutated by sequencing. Six of them (40%), however, required cloning before sequencing, because of low allelic burden. Classic techniques such as genomic sequencing may therefore miss patients with mutations. Given its sensitivity, HRM (and nested HRM) can be used in routine diagnosis and seems to be the most efficient of current techniques for detection of JAK2 exon 12 mutations., (Copyright © 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
43. Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma.
- Author
-
Henry L, Lavabre-Bertrand T, Douche T, Uttenweiler-Joseph S, Fabbro-Peray P, Monsarrat B, Martinez J, Meunier L, and Stoebner PE
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers blood, Disease-Free Survival, Female, Humans, L-Lactate Dehydrogenase blood, Male, Melanoma pathology, Middle Aged, Neoplasm Metastasis diagnosis, Neoplasm Staging, Predictive Value of Tests, Prognosis, Protein Subunits blood, ROC Curve, Recurrence, Survival Analysis, Young Adult, Melanoma blood, Melanoma diagnosis, Proteasome Endopeptidase Complex blood
- Abstract
Plasmatic proteasome (p-proteasome) also called circulating proteasome has recently been described as a tumor marker. We investigated the diagnostic and prognostic accuracies of p-proteasome levels in a melanoma population classified according to the American Joint Committee on Cancer staging system. Using an ELISA test, we measured p-proteasome levels in 90 patients and 40 controls between March 2003 and March 2008. The subunit composition of p-proteasomes was determined in metastatic melanoma by proteomic analysis. The mean p-proteasome levels were correlated with stages (P < 0.0001; r(S) = 0.664). They were significantly higher in patients with stage IV and stage III with lymph node metastasis (9187 ± 1294 and 5091 ± 454 ng/ml, respectively) compared to controls (2535 ± 187 ng/ml; P < 0.001), to stage I/II (2864 ± 166 ng/ml; P < 0.001) and to stage III after curative lymphadenectomy (2859 ± 271 ng/ml; P < 0.001). The diagnostic accuracy of p-proteasome was evaluated by receiver operating characteristic analysis. With a cut-off of 4300 ng/ml, diagnostic specificity and sensitivity of p-proteasome for regional or visceral metastases were respectively 96.3% and 72.2%. In univariate analysis, high p-proteasome levels (>4300 ng/ml) were significantly correlated with an increased risk of progression [hazard ratio (HR) = 7.34; 95% CI 3.54-15.21, P < 0.0001] and a risk of death (HR = 5.92; 95% CI 2.84-12.33, P < 0.0001). In multivariate analysis, high p-proteasome levels were correlated with a poorer clinical outcome in the subgroup analysis limited to patients with disease stages I, II and III. Proteomic analysis confirmed the presence of all proteasome and immunoproteasome subunits. Taken together, these results indicate that p-proteasomes are a new marker for metastatic dissemination in patients with melanoma., (© 2010 John Wiley & Sons A/S.)
- Published
- 2010
- Full Text
- View/download PDF
44. Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib.
- Author
-
Gaillard JB, Arnould C, Bravo S, Donadio D, Exbrayat C, Jourdan E, Reboul D, Chiesa J, and Lavabre-Bertrand T
- Subjects
- Antineoplastic Agents therapeutic use, Benzamides, Cohort Studies, DNA Mutational Analysis, Exons, Gene Deletion, Gene Frequency, Genetic Association Studies, Genetic Testing methods, Humans, Imatinib Mesylate, Nucleic Acid Denaturation genetics, Protein Isoforms genetics, Temperature, Drug Resistance, Neoplasm genetics, Fusion Proteins, bcr-abl genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Piperazines therapeutic use, Pyrimidines therapeutic use
- Abstract
Chronic myeloid leukemia (CML) patients treated with imatinib develop frequent resistance generally due to a point mutation. Recently, large rearrangements of abl sequence have also been described. In this study, we focused on the complete deletion of exon 7. We screened for bcr-abl(delexon7) in 63 resistant patients by high-resolution melting (HRM) analysis and direct sequencing. Moreover, we analyzed expression of abl(delexon7) and bcr-abl(delexon7) in 17 CML patients at diagnosis, 32 patients at resistance, and 20 negative controls by quantitative PCR or fragment length analysis. bcr-abl(delexon7) was detected on 34 (54%) among 63 resistant patients by HRM, showing an increase in the sensitivity of screening, because only 3.2% could be detected by direct sequencing. This deletion was not associated with a point mutation (P = 0.3362). In addition, abl(delexon7) was found in all tested samples with the same pattern of expression, suggesting an alternative splicing mechanism. In the bcr-abl component, there was no statistical difference between CML patients at diagnosis and resistant patients (P = 0.2815) as regarding bcr-abl(delexon7) proportion, thus arguing against involvement of deletion in resistance. Moreover, among two patients harboring bcr-abl(delexon7) at diagnosis, one experienced a complete disappearance of this transcript, and the other decreased >75% at resistance. In conclusion, bcr-abl(delexon7) is frequently observed in CML patients when using sensitive techniques. It seems to be the result of an alternative splicing mechanism and to be independent from the occurrence of resistance., (©2010 AACR.)
- Published
- 2010
- Full Text
- View/download PDF
45. Constitutive expression of MC1R in HaCaT keratinocytes inhibits basal and UVB-induced TNF-alpha production.
- Author
-
Garcin G, Le Gallic L, Stoebner PE, Guezennec A, Guesnet J, Lavabre-Bertrand T, Martinez J, and Meunier L
- Subjects
- Cell Line, Humans, Receptor, Melanocortin, Type 1 genetics, alpha-MSH pharmacology, Gene Expression Regulation radiation effects, Keratinocytes metabolism, Receptor, Melanocortin, Type 1 metabolism, Tumor Necrosis Factor-alpha metabolism, Ultraviolet Rays
- Abstract
Alpha-melanocyte stimulating hormone (alpha-MSH) binds to melanocortin-1 receptor (MC1R) on melanocytes to stimulate pigmentation and modulate various cutaneous inflammatory responses. MC1R expression is not restricted to melanocytic cells and may be induced in keratinocytes after UVB exposure. We hypothesized that MC1R signaling in keratinocytes, wherein basal conditions are barely expressed, may modulate mediators of inflammation, such as nuclear factor-kappa B (NF-kappaB) and tumor necrosis factor-alpha (TNF-alpha). Therefore, we generated HaCaT cells that stably express human MC1R or the Arg151Cys (R151C) nonfunctional variant. We demonstrate that: (1) the constitutive activity of MC1R results in elevated intracellular cAMP level, reduced NF-kappaB activity and decreased TNF-alpha transcription; (2) binding of alpha-MSH to MC1R and the subsequent increase in cAMP production do not inhibit TNFalpha-mediated NF-kappaB activation; (3) MC1R signaling is sufficient to strongly inhibit UVB-induced TNF-alpha expression and this inhibitory effect is further enhanced by alpha-MSH stimulation. Our findings suggest that the constitutive activity of the G-protein-coupled MC1R in keratinocytes may contribute to the modulation of inflammatory events and immune response induced by UV light.
- Published
- 2009
- Full Text
- View/download PDF
46. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
- Author
-
Henry L, Lavabre-Bertrand T, Vercambre L, Ramos J, Carillo S, Guiraud I, Pouderoux P, Bismuth M, Valats JC, Demattei C, Duny Y, Chaze I, Funakoshi N, Bureau JP, Daurès JP, and Blanc P
- Subjects
- Area Under Curve, Carcinoma, Hepatocellular complications, Carcinoma, Hepatocellular pathology, Case-Control Studies, Female, Humans, Liver Cirrhosis complications, Liver Cirrhosis pathology, Liver Neoplasms complications, Liver Neoplasms pathology, Logistic Models, Male, Middle Aged, Prospective Studies, Sensitivity and Specificity, alpha-Fetoproteins analysis, Biomarkers, Tumor blood, Carcinoma, Hepatocellular blood, Liver Cirrhosis blood, Liver Neoplasms blood, Proteasome Endopeptidase Complex blood
- Abstract
Background: Proteasomes are the main non-lysosomal proteolytic structures which regulate crucial cellular processes. Circulating proteasome levels can be measured using an ELISA test and can be considered as a tumour marker in several types of malignancy. Given that there is no sensitive marker of hepatocellular carcinoma (HCC) in patients with cirrhosis, we measured plasma proteasome levels in 83 patients with cirrhosis (33 without HCC, 50 with HCC) and 40 controls., Methods and Results: Patients with HCC were sub-classified into three groups according to tumour mass. alpha-Fetoprotein (AFP) was also measured. Plasma proteasome levels were significantly higher in patients with HCC compared to controls (4841 (SEM 613) ng/ml vs 2534 (SEM 187) ng/ml; p<0.001) and compared to patients with cirrhosis without HCC (2077 (SEM 112) ng/ml; p<0.001). This difference remained significant when the subgroup of patients with low tumour mass (proteasome level 3970 (SEM 310) ng/ml, p<0.001) was compared to controls and patients with cirrhosis without HCC. Plasma proteasome levels were independent of the cause of cirrhosis and were weakly correlated with AFP levels. With a cut-off of 2900 ng/ml, diagnostic specificity for HCC was 97% with a sensitivity of 72%, better than results obtained with AFP. Diagnostic relevance of plasma proteasome measurement was also effective in low tumour mass patients (sensitivity 76.2% vs 57.1% for AFP)., Conclusion: The plasma proteasome level is a reliable marker of malignant transformation in patients with cirrhosis, even when there is a low tumour mass.
- Published
- 2009
- Full Text
- View/download PDF
47. [An unusual tumor of the endometrium].
- Author
-
Perrochia H, Rubay R, Gaujoux AF, Chapuis H, Lavabre-Bertrand T, and Roger P
- Subjects
- Carcinoma, Squamous Cell pathology, Endometrial Neoplasms pathology, Female, Humans, Middle Aged, Neoplasm Invasiveness, Carcinoma, Squamous Cell diagnosis, Endometrial Neoplasms diagnosis
- Published
- 2009
- Full Text
- View/download PDF
48. Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
- Author
-
Stoebner PE, Le Gallic L, Berthe ML, Boulle N, Lallemant B, Marque M, Gaspard C, Delfour C, Lavabre-Bertrand T, Martinez J, and Meunier L
- Subjects
- Carcinoma, Basal Cell genetics, Carcinoma, Basal Cell metabolism, Carcinoma, Basosquamous genetics, Carcinoma, Basosquamous metabolism, Carcinoma, Basosquamous pathology, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Down-Regulation, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Keratosis, Actinic genetics, Keratosis, Actinic metabolism, Keratosis, Actinic pathology, RNA, Messenger genetics, RNA, Messenger metabolism, Reverse Transcriptase Polymerase Chain Reaction, Skin Neoplasms genetics, Skin Neoplasms metabolism, Thymidine Phosphorylase biosynthesis, Carcinoma, Basal Cell pathology, Skin Neoplasms pathology, Thymidine Phosphorylase genetics
- Abstract
Thymidine phosphorylase (TP)/platelet-derived endothelial cell growth factor is associated with tumor angiogenesis. We evaluated the TP mRNA and protein expression in basal cell carcinomas (BCC) and in various skin tumors including numerous BCC histological simulants. Immunohistochemistry was performed on 99 paraffin sections of formalin-fixed skin tumors using monoclonal antibodies (mAb) against TP. TP mRNA levels were measured by real time RT-PCR in whole BCCs (wBCC) and laser capture microdissected (LCM) BCC tumor cells. TP immunostaining was negative in all BCC variants and in most of the benign trichogeneic tumors studied. By contrast, TP was constantly immunodetected in actinic keratosis (AK), squamous cell carcinomas (SCC), syringomatous carcinomas (SC), basosquamous carcinomas (BSC) and melanomas. TP mRNA levels were low and statistically not different in wBCC and normal skin but were strongly downregulated in LCM-BCC as compared with LCM-normal epidermis. We concluded that (i) anti-TP mAb is an useful marker to differentiate BCC from AK, SCC, BSC and SC but not from trichoblastic tumors, (ii) the lack of TP protein expression in BCC tumoral cells is linked to transcriptional regulatory mechanisms, (iii) the low TP mRNA levels in whole BCC may be related to the low intra-tumoral microvessel density, the slow growth and the very low metastatic potential of these tumors.
- Published
- 2008
- Full Text
- View/download PDF
49. Association of familial pernicious anaemia and hereditary haemochromatosis.
- Author
-
Bonafoux B, Henry L, Delfour C, Arnaud A, Brun S, Mercier E, Jourdan E, Carillo S, Funakoshi N, Bureau JP, Blanc P, and Lavabre-Bertrand T
- Subjects
- Adult, Anemia, Pernicious drug therapy, Anemia, Pernicious genetics, Hemochromatosis genetics, Hemochromatosis Protein, Histocompatibility Antigens Class I genetics, Humans, Male, Membrane Proteins genetics, Middle Aged, Mutation, Vitamin B 12 administration & dosage, Vitamin B 12 blood, Vitamin B 12 therapeutic use, Anemia, Pernicious complications, Hemochromatosis complications
- Abstract
We report the case of a 54-year-old patient presenting with a typical pernicious anaemia. His mother was diagnosed with unquestionable pernicious anaemia 5 years previously. Serum ferritin was strongly increased (1,160 microg/l, normal range 29-380), with a transferrin saturation of 95%. We found a homozygous C282Y mutation of the HFE gene in our patient, his mother being heterozygous. The son of our patient was compound C282Y/H63D heterozygous without detectable pernicious anaemia. This seems to be the first report of an association between familial pernicious anaemia and hereditary haemochromatosis. The simultaneous occurrence of the 2 diseases in the same patient helps to delineate the relative contribution of each of them to iron metabolism and erythropoiesis: iron overload was only moderately increased and responded rapidly to phlebotomies, whereas haemochromatosis did not modify the cytologic presentation of pernicious anaemia., (2008 S. Karger AG, Basel)
- Published
- 2008
- Full Text
- View/download PDF
50. Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment.
- Author
-
Henry L, Carillo S, Jourdan E, Arnaud A, Brun S, and Lavabre-Bertrand T
- Subjects
- Female, Humans, Hydroxyurea therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Middle Aged, Thrombocythemia, Essential diagnosis, Thrombocythemia, Essential drug therapy, Janus Kinase 2 genetics, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Lymphoproliferative Disorders genetics, Point Mutation, Thrombocythemia, Essential genetics
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.